Nanobiotix (NASDAQ:NBTX) Given New $36.00 Price Target at Guggenheim

Nanobiotix (NASDAQ:NBTX) had its price objective raised by Guggenheim from $26.00 to $36.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price target would suggest a potential upside of 16.47% from the stock’s previous close.

NBTX has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. TD Cowen restated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Nanobiotix Trading Down 9.3%

NASDAQ NBTX traded down $3.16 on Thursday, reaching $30.91. The company had a trading volume of 17,065 shares, compared to its average volume of 45,822. The stock’s 50 day moving average is $27.90 and its 200-day moving average is $23.20. Nanobiotix has a 52 week low of $2.99 and a 52 week high of $41.89.

Nanobiotix (NASDAQ:NBTX) last issued its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million during the quarter. Research analysts forecast that Nanobiotix will post -1.18 EPS for the current year.

Institutional Trading of Nanobiotix

Hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its holdings in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Optiver Holding B.V. acquired a new stake in shares of Nanobiotix during the third quarter worth $101,000. Marshall Wace LLP acquired a new stake in shares of Nanobiotix during the fourth quarter worth $220,000. Finally, Millennium Management LLC bought a new stake in Nanobiotix in the 4th quarter valued at $390,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.